You have almost certainly relied on Bodycote without knowing it. Jet engine turbine blades, car gearbox shafts and hip implants often pass through its furnaces or presses. Bodycote does not make these parts. It makes them tougher and longer-lasting, charging manufacturers for each batch.

That quiet, essential role has now drawn the attention of private equity. On 1 September 2026 the board recommended a cash Takeover by Veritas Capital, a New York investor that specialises in aerospace and defence, worth 940p a share. That is 932.8p in cash plus the 7.2p interim dividend. Veritas was not the first to try. Apollo made proposals in May before walking away on 5 June, and CVC was still weighing its Options when the Veritas deal was announced.

So the question for shareholders has changed: is 940p a fair price for a Business partway through a turnaround, and might another bidder pay more?

How the business makes money

Bodycote (LSE:BOY) is the world's largest independent heat treatment provider, with 136 sites in 22 countries at the end of 2025. Customers send in components, and Bodycote uses controlled heating, cooling, pressure and surface treatments to change how the metal behaves. It is paid mostly per part, so Revenue tracks how busy its customers' factories are.

The group reports in two main divisions. Precision Heat Treatment is the larger, more traditional business, with a 16.0% adjusted Margin in 2025. Specialist Technologies includes hot isostatic pressing (HIP), which uses heat and very high pressure to close internal flaws in castings and 3D-printed parts, plus specialist stainless steel processes and coatings. It is the more valuable division, with a 27.1% margin in 2025.

In 2025 aerospace and defence made up 34% of core revenue. Automotive and industrial markets each made up 22%, energy 11%, and consumer, medical and other markets the remaining 11%. Western Europe produced half of group revenue and North America 38%.

Recent performance

2025 was difficult. Revenue for the year to 31 December 2025 fell 4.0% to £727.1m. Adjusted operating profit dropped to £114.3m from £129.0m, the margin narrowed from 17.0% to 15.7%, and adjusted EPS fell 8.6% to 44.4p. The full-year dividend stayed at 23.0p.

The first half of 2026 was much stronger. In the six months to 30 June 2026 revenue rose 3.3% to £381.2m, with organic growth of 6.5% and 9.6% in the core business. Adjusted operating profit climbed 10.7% to £61.0m, and the margin improved to 16.0%. Adjusted EPS grew 18.3% to 25.2p, helped by share buybacks, and the Interim Dividend rose to 7.2p.

Aerospace and defence revenue grew by roughly a quarter on an organic basis, while automotive fell about 4% because of continued weakness in Western Europe. Net debt, excluding leases, rose to £135.2m, and free Cash Flow slipped to £14.5m as Capital spending increased.

Strategy and catalysts

Chief executive Jim Fairbairn, who joined in 2024, has organised his plan around three themes: Optimise, Perform and Grow. Optimise is a clean-up of the site network. By the half-year, 27 of 31 planned closures, disposals and consolidations were complete, including the sale of ten non-core French sites for £19m. The programme is expected to cost around £60m in total and deliver at least £15m of annual savings by mid-2027, and management has said it may extend it to more automotive and industrial sites.

On the Grow side, Bodycote bought Spectrum Thermal Processing, an aerospace-focused heat treater in Rhode Island, in January 2026, and is adding HIP capacity. The targets for 2028 are ambitious: margins above 20%, 35–40% of revenue from Specialist Technologies, and a return on capital employed of 15–20%.

The takeover is now the main event. The Veritas deal will be carried out through a scheme of arrangement, which needs approval from 75% of the shares voted plus competition and regulatory clearances. Completion is expected in the first quarter of 2027. Veritas has said it will keep the management team and review the business in the first year, which could include selling the non-core automotive and general industrial operations. Bodycote suspended its buyback on 2 September.

Valuation talking points

The offer values Bodycote's equity at about £1.64bn and the whole business, including debt, at about £1.84bn. The 940p price is a 37.5% premium to the three-month volume-weighted average share price up to 21 May 2026, the day before bid talk became public.

By our own simple calculation, the cash price is about 21 times 2025 adjusted earnings per share. The Enterprise value is roughly 16 times 2025 adjusted operating profit. Those are demanding multiples for a company whose earnings fell last year. They look more reasonable if the first-half recovery continues and the 2028 margin target is reached.

Competition has clearly pushed the price up. In August, Veritas and CVC had each proposed around 914p–915p. With CVC still considering its position, some investors will wonder whether there is more to come.

The bull case

  • The offer is in cash and recommended by the board, at a premium of more than a third to the undisturbed share price.
  • CVC's continued interest leaves some chance of a counter-bid.
  • Aerospace and defence, now about half of Specialist Technologies revenue, grew by around 25% organically in the first half of 2026.
  • Optimise savings should keep lifting margins, whoever owns the business.

The bear case

  • The upside is now largely capped at 940p unless a rival bidder makes a higher offer.
  • Regulatory clearances in several countries could delay or complicate a deal expected to close in early 2027.
  • If the deal fails, the shares would lose the bid support and depend on a turnaround that has only just begun.
  • Weakness in Western European automotive markets remains a drag, and 2025 showed how quickly volumes can fall.
  • Net Debt and capital spending were both rising before the bid.

The bottom line

Bodycote sells toughness, one component at a time, to industries where failure is not an option. Private Equity has spotted what the market often overlooked: a hard-to-copy network shifting towards higher-growth aerospace, defence and energy work.

For shareholders, the decision now comes down to certainty against possibility. The Veritas offer turns a mid-turnaround industrial company into cash in 2027. Rejecting it means betting either on a better offer from CVC or on management reaching its 2028 targets without bid support. The scheme document and any further move by CVC are the next things to watch.